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Abstract
Signalling through the BMP4/Smad1 pathway promotes corticospinal tract axon regeneration and functional recovery in mice.
However, unlike humans and rats, mice do not cavitate. Here, we investigated if activation of the BMP4/Smad1 pathway
promotes axon regeneration and functional recovery in a rat model that cavitates. We show that dorsal root ganglion neurons
(DRGN) in injury models, including the non-regenerating dorsal column (DC) and the regenerating sciatic nerve (SN) crush and
preconditioning (p) SN + DC (pSN +DC) paradigms, regulate the BMP4/Smad1 signalling pathway. For example, mRNA
expression of positive regulators of the BMP4/Smad1 pathway was highly up-regulated whilst negative regulators were signif-
icantly down-regulated in DRGN in the regenerating SN and pSN +DC models compared to non-regenerating DC models,
matched by concomitant changes in protein expression detected in DRGN by immunohistochemistry. BMP4 peptide promoted
significant DRGN survival and disinhibited neurite outgrowth in vitro, whilst AAV-BMP4 delivery in vivo stimulated DC axon
regeneration and functional recovery in a model that cavitates. Our results show that activation of the BMP4/Smad1 pathway is a
potential therapeutic target in the search for axon regenerative signalling pathways in the CNS.
Keywords Spinal cord injury . BMP4 . Smad1 . Dorsal root ganglion neurons . Dorsal column . Axon regeneration
Introduction
Several signalling pathways have been associated with axon
regeneration after spinal cord injury (SCI). These include the
phophoinositide-3-kinase (PI3K) and extracellular receptor
kinase (ERK) pathways that are essential for axon assembly
and neurotrophin-induced axonal branching [1–3]. The PI3K-
Akt pathway also regulates local protein synthesis via the
mammalian target of rapamycin (mTOR) signalling pathway
with adult neurons requiring mTOR signalling to promote
axon regeneration [4]. It is not known if mTOR signalling
plays a role in the regeneration of ascending long-tract dorsal
root ganglion neuron (DRGN) dorsal column (DC) projec-
tions, but an mTOR independent pathway is implicated, since
pSN also promotes DC axon regeneration [5, 6]. The genes of
many PI3K independent axogenic signalling proteins are
transcribed in axotomised DRGN [7–9]. Prominent among
the latter is the bone morphogenetic protein 4 (BMP4)/
mothers against decapentaplegic homologue 1 (Smad1) path-
way. Smad1 activation, nuclear accumulation and gene tran-
scription require BMP receptor (BMPR) binding and histone
4 (H4) acetylation [10] when BMP/Smad and PI3K/Akt path-
ways interact to effect axogenesis. For example, (1) PI3K/Akt
induces nuclear localisation of BMP4-activated Smad1 and
regulates Smad induction of axon regeneration-related tran-
scription factors and (2) BMP4 activates Akt by suppression
of PTEN, stimulation of MAPK and autocrine induction of
growth factor secretion [11, 12].
BMP4/Smad1 signalling stimulates peripheral DRGN ax-
on growth developmentally, and down-regulation of the path-
way with age correlates with a decline in axon growth poten-
tial [13]. SN axotomy up-regulates Smad1 [10] and BMP2/4
injected into DRG potentiates SN growth [14]. DRGN neurite
outgrowth is suppressed after knockdown of the BMP co-
receptor (repulsive guidance molecule b-RGMb), and con-
versely, inhibition of the BMPR antagonist Noggin in mature
DRGN in vivo potentiates SN axon regeneration [15]. The
inactivation of Smad1 in DRGN after DC lesions correlates
with failed axon regeneration, whereas DRG injection of
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BMP4 activates Smad1 and promotes DC axon regeneration
in the lesioned adult mouse cord [13].
However, the mouse cord does not cavitate after SCI
whereas the rat cord does [16], and hence, the impact of
BMP4/Smad1 activation in a model that cavitates as in
humans remains to be investigated. Here, we used the rat
model, which cavitates, to determine the contribution of the
BMP4/Smad1 signalling pathway on DC axon regeneration
and return of locomotor and sensory function. We show that
BMP4/Smad1 is activated when DRGN axons regenerate af-
ter an SN and pSN + DC lesions, BMP4 peptide promotes
disinhibited DRGN neurite outgrowth in the presence of in-
hibitory CNS myelin extracts (CME), whilst BMP4 over-
expression in DRGN in vivo enhances DC axon regeneration
and promotes functional recovery in adult rats, despite the
presence of spinal cord cavities. These results suggest that
the BMP4/Smad1 pathway is a potential target for therapeutic
intervention in SCI patients.
Methods
Animals
Adult (6–8-week old) female Sprague-Dawley rats (180–
250 g) (Charles River,Margate, UK)were used. Animals were
maintained in the animal facility of University of
Birmingham, UK, under standard conditions (21 °C, 12-h
light-dark cycle) with free access to food and water. All sur-
gery was performed in strict accordance to the guidelines of
both the UK Animals Scientific Procedures Act, 1986 and the
Revised European Directive 1010/63/EU. Experiments were
licenced by the UK Home Office and ethically approved by
the University of Birmingham’s animal welfare and ethical
review board. Experiments also conformed to the recommen-
dations of the use of animals by the Federation of the
European Laboratory Animal Science Associations.
Experimental Design
For in vivo microarray experiments, four adult female
Sprague-Dawley rats/group (n = 12 rats/group (3 independent
repeats)) were randomly assigned to (1) uninjured intact con-
trols (IC), (2) sham-treated controls (sham: partial
laminectomy but no DC crush injury), (3) non-regenerating
DC model (DC) that received a DC lesion alone, (4)
regenerating SN model (SN) that received a SN lesion alone,
and (5) regenerating pre-conditioning SN lesion (pSN) + DC
injury model (pSN +DC-pSN lesion performed 7 days before
the DC lesion). Tissues were harvested at 10 days after DC,
SN and pSN +DC lesions for the microarray, qRT-PCR and
immunohistochemistry studies (Fig. 1a) and at 6 weeks after
DC lesion for the in vivo adeno-associated virus 8 (AAV8;
AAV serotype 8) delivered BMP4 (AAV-BMP4) studies (Fig.
1b). AAV8 has previously been shown by others and our-
selves to preferentially transduce large-diameter neurons that
form the ascending tracts of the DC [17]. All in vivo experi-
ments, except the microarray study, contained six rats/group,
repeated on three independent occasions (total n = 18
rats/group/test) and performed by an investigator masked to
the treatment conditions. Ten days after DC lesion was chosen
since Q-PCR and immunohistochemistry studies at 1, 3, 5, 7,
10 and 17 days after DC lesion showed the greatest gene/
protein changes between groups (not shown).
To test the potential of AAV-BMP4 to disinhibit DC axon
regeneration and enhance functional recovery in vivo, groups
of six adult female Sprague-Dawley were randomly assigned
to treatment groups. At 1 week before DC injury (week 1),
groups of animals received intra-DRG injection of either con-
trol AAV8-Null (Vector Biolabs, Malvern, PA, USA; AAV
serotype 8 with a CMV promoter but no transgene) (DC +
AAV-Null) or AAV-BMP4 (DC + AAV-BMP4) (Fig. 1b).
After 7 days, a group of animals was designated as sham-
treated control (sham). Animals from each group received
either a sham (partial laminectomy and exposure of the spinal
cord but no DC lesion) or DC injury (partial laminectomy
followed by crush injury of the DC tracts) [16] 7 days later.
Animals were allowed to survive for 6 weeks during which
behavioural tests were performed by individuals masked to
the treatment conditions at baseline, 2 days and then weekly
at 1–6 weeks after injury [18, 19]. Electrophysiology was
performed at 6 weeks after injury before harvesting tissues
for immunohistochemistry (Fig. 1b) [19]. All in vivo experi-
ments were repeated on three independent occasions (total n =
18 rats/group/treatment).
Surgery and Tissue Harvesting
All animals were injected with Buprenorphine to provide an-
algesia before anaesthesia using 5% isoflurane with 1.8 l/min
O2. After a partial laminectomy, DC were crushed bilaterally
at the level of T8 using calibrated watchmaker’s forceps [16,
20, 21]. The tips of the forceps, separated to a width of 1 mm,
were inserted into the cord through the dorsal meninges to a
depth of 1 mm and the DC crushed by tip approximation. The
left SN was exposed at mid-thigh level and crushed using fine
forceps at the level of the sacrotuberous ligament. In the
pSN +DC model, SN were crushed 1 week before DC crush
injury. Rats were housed under standard conditions after sur-
gery along with their cage mates in groups of four rats. For the
microarray and immunohistochemistry studies, rats were
killed at 10 days after DC lesion by CO2 exposure when L4/
L5 DRG was harvested from the ipsilateral (treated) and con-
tralateral (untreated) sides. DRGwere snap frozen in liquid N2
before RNA extraction, and for immunohistochemistry, ani-
mals were intracardially perfused with 4% formaldehyde in
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phosphate-buffered saline (PBS) and both ipsilateral and con-
tralateral L4/L5 DRG processed as described below.
Intra-DRG Injections
The left L4/5 DRG were exposed and injected as described by
us previously [17] with either 1013 viral genomes of AAV-Null
(control; Vector Biolabs) or AAV-BMP4 (gift from Hongyang
Zou, Mount Sinai School of Medicine, New York, USA) in a
total volume of 5-μl sterile PBS using a glass micropipette.
Microarray Analysis
RNA was extracted from a total of 12 DRG/treatment (n = 4
DRG/treatment, 3 independent repeats) harvested at 10 days
after DC lesion from each experimental group detailed above
using the RNeasy kit (Qiagen Ltd., Crawley, UK) according to
the manufacturer’s instructions. The rat genome AROS™
V3.0 set (Operon Biotechnologies GmbH, Cologne,
Germany) containing 29,962 long-mer probes representing
22,012 genes and 27,044 gene transcripts was used for the
microarray analysis (Read et al., 2009). Briefly, either Cy3-
or Cy5-labelled oligonucleotide probes were hybridised and
slides were scanned with an Axon GenePix 4000B scanner
(Molecular Devices Ltd., Berkshire, UK); background fluo-
rescence values for Cy3 and Cy5 channels were subtracted
and data analysed using GeneSpring GX7 (Agilent,
Berkshire, UK) normalised by the Lowess method. Data were
filtered below the P < 0.05 threshold, and fold changes > 2
above sham control levels were taken as significant. Each
condition was replicated × 4 in duplicate.
Quantitative Real-Time PCR
RNA was extracted from n = 6 DRG/treatment, which were
pooled together at 10 days after DC lesion, using the
RNeasy kit (Qiagen Ltd., Crawley, UK) according to the
manufacturer’s instructions. Experiments were repeated on
three independent occasions with total n = 18 DRG/treat-
ment. Selected genes of the BMP4/Smad1 pathway were
validated by Q-PCR using pre-validated primer sequences
(Table 1) from complementary DNA prepared from
Fig. 1 Experimental design of a
in vivo microarray and
immunohistochemistry studies
and b the in vivo AAV-BMP4
study
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extracted mRNA, and Q-PCR was performed using
LightCycler Q-PCR machine (Roche, Burgess Hill, UK) fol-
lowing previously published methods [22]. Fold changes
were computed using the ΔΔCt method and the mean ±
SEM is presented from the three independent repeats.
Immunohistochemistry of DRG
Ipsilateral and contralateral L4/L5 DRG (n = 6 DRG/treatment,
3 independent repeats; total n = 18 DRG/treatment) from
perfusion-fixed rats were cryoprotected through a graded series
of sucrose solutions and blocked in optimal cutting temperature
(OCT) compound (TAAB Laboratories, Peterborough, UK).
DRG cryosections were adhered onto charged glass slides and
sections from the middle of each DRG were chosen for immu-
nohistochemistry. After washing in PBS, non-specific antibody
binding was blocked with 3% bovine serum albumin diluted in
PBS containing 0.1% Triton-X100 before overnight incubation
at 4 °C with the relevant primary antibodies (Table 2).
Regenerating axons in the DC were detected using GAP-43
immunohistochemistry since Cholera toxin B labelling in our
hands did not label regenerating axons by retrograde transport
labelling in the rat [23], despite others demonstrating successful
labelling [6, 24]. Sections not exposed to primary antibody
were included as negative controls in each run, washed in
PBS, incubated with relevant secondary antibodies conjugated
to either Alexa488 or Alexa594 for 1 h at room temperature
(RT; Table 2), washed in several changes of PBS and mounted
using Vectashield containing DAPI (Vector Laboratories,
Peterborough, UK). Sections were examined using a Zeiss
epi-fluorescent microscope attached to an Axiocam HRc run
by Axiovision software (all from Zeiss, Hertfordshire, UK).
Negative controls were used to set the background threshold
level for each antibody before image capture.
Primary DRGN Cultures
Primary adult rat (Sprague-Dawley rats, 170–220 g, Charles
River) DRGN were prepared from intact DRG according to
our previously published methods [25]. DRG cells from ipsi-
lateral and contralateral L4–7DRGpairs were dissociated using
0.025% collagenase (Sigma, Poole, UK) and plated (500/well)
in supplemented neurobasal-A (NBA; containing B-27 supple-
ment and L-glutamine; all from Invitrogen, Paisley, UK), plated
in 8-well chamber slides pre-coated with 100 μg/ml poly-D-
lysine plus 10 μg/ml of laminin (both from Sigma) and, after
settling overnight, incubated with appropriate treatments for
3 days at 37 °C and 5% CO2, as described below.
Treatment of DRGN Cultures with BMP4 Peptide
To establish if BMP4 promoted disinhibited DRGN neurite
outgrowth, cultures prepared in 8-well chamber slides as de-
scribed above were treated with NBA alone (control) or with
NBA plus 50, 100, 150 and 200 ng/ml of BMP4 peptide
(Peprotech, London, UK), in the presence of 200 μg/ml CME
[26]. Cultures were incubated with appropriate treatments for
3 days before fixation in 4% paraformaldehyde and subjected to
immunocytochemistry as described below. All slides were
masked after treatment for analysis by a second unbiased inves-
tigator. Four days later, immunocytochemistry for βIII-tubulin
was then used to quantify DRGN neurite outgrowth as de-
scribed below. Individual treatments in each experimental run
were performed in triplicate and runs were repeated on three
independent occasions (total n = 9 wells/treatment).
Immunocytochemistry of Cultured DRGN
After 4 days of treatment, DRGN cultures were immersion
fixed in 4% formaldehyde for 10 min at RT, permeabilised
Table 1 List of primers used for
the BMP4/Smad1 pathway Gene Primer sequence Ref
smad1 Forward: 5′-ACCTGCTTACCTGCCTCCTG-3′ Kuo et al., 2011
Reverse: 5′-CATAAGCAACCGCCTGAACA-3′
smad5 Forward: 5′-CTGGGATTACAGGACTTGACC-3′ Kuo et al., 2011
Reverse: 5′-AAGTTCCAATTAAAAAGGGAGGA-3′
smad8 Forward: 5′-GTATCATCGCCAGGATGTCA-3′ Yew et al., 2005
Reverse: 5′- TGTGGGGAGCCCATCTGAGT-3′
bmp-4 Forward: 5′ GGCAGAGGAGGAGGGAGGGAGGGAAGGAGC-3′ Kawai and Sugiura, 2001
Reverse: 5′-CAGTAGCGGGCTCGCCAGCAGCAGCTCCTG-3′
creb-p Forward: 5′-AAGCTGAAAGTCAACAAATGACAGTT-3′ Shankar et al., 2005
Reverse: 5′-TGGACTGTCTGCCCATTGG-3′
mkk3/6 Forward: 5′-GGCCCCTGAAAGAATAAACCC-3′ Galan-Moya et al., 2011
Reverse: 5′-CGAAGGATGGCCAACTCAATC-3′
gapdh Forward: 5′-ACCACAGTCCATGCCATCAC-3′ Xu et al., 2010
Reverse: 5′-TCCACCACCCTGTTGCTGTA-3′
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and non-specific binding blocked using 3% BSA containing
0.1% Triton X-100 in PBS. After incubation with mouse
anti-βIII-tubulin antibody (to label DRGN; Table 2) for 1 h
at RT, cells were washed in PBS, incubated with Alexa 488
anti-mouse secondary antibody (Table 2) for 1 h at RT, washed
in PBS and mounted using Vectashield containing DAPI
(Vector Laboratories, Peterborough, UK) and stored at 4 °C
until required. Negative staining controls were included in
each run in which the primary antibody was omitted and used
to set the background fluorescence thresholds for each anti-
body when capturing images.
DRGN Survival and Neurite Outgrowth
With the experimenter masked to the treatment conditions,
mean numbers of βIII-tubulin+ DRGN with neurites and
mean neurite lengths were quantified in nine quadrants/
well using a Zeiss Axioplan 2 fluorescent microscope
equipped with an Axiocam HRc and Axiovision Software
(all from Zeiss, Hertfordshire, UK) [25]. The longest
neurite was measured using Axiovision from at least 30
DRGN/well/treatment, whilst total DRGN counts to assess
survival were made over the entire well for each treatment
condition (n = 3 wells/treatment, 3 independent repeats; to-
tal n = 9 wells/treatment).
BMP4 Enzyme-Linked Immunosorbent Assay
The levels of BMP4 in DRG and in the spinal cord lesion-
site tissue were detected by ELISA using a rat BMP4
ELISA kit, according to the manufacturer’s instructions
(ElisaGenie, London, UK). DRG (n = 6/treatment, 3 inde-
pendent repeats; total n = 18 DRG/treatment) and an area
of T8 spinal cord (n = 6/treatment, 3 independent repeats;
total n = 18 cords/treatment) that encompassed the lesion
site (1 cm in length × 0.5 mm centred on the lesion
epicentre) were collected, weighed and equal amounts
were homogenised in 1 ml of tissue extraction buffer
(100 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EGTA,
1 mM EDTA, 1% Triton X-100 and 0.5% sodium
deoxycholate). Samples were kept at 4 °C for 30 min
before clarification by centrifugation at 13,000 rpm at
4 °C for 15 min. ELISA was performed on 10 μl of each
sample, in duplicate and repeated on three independent
occasions.
Quantification of DC Axon Regeneration
Numbers of regenerating axons in the DC were quantified as
previously described [19, 27]. Composites of serial
parasagittal sections through the entire DCwere reconstructed
by collecting images of GAP-43-labelled axons in the spinal
cord from all serial 50-μm-thick sections (∼ 70–80 sections/
cord; n = 6 rats/treatment, 3 independent repeats; total n = 18
rats/group). On each reconstructed composite image, the num-
ber of GAP43+ axons intersecting a dorsoventral line drawn
across the cord was counted at intervals of 2 mm from 4 mm
above to 6 mm below the lesion site. Axon number was cal-
culated as % axons seen at 4 mm above the lesion, where the
DCwas intact. The distance beyond the epicentre of the lesion
towards the rostral end was scored as positive and the caudal
end as negative distances.
Electrophysiology
Compound action potentials (CAP) were recorded at 6 weeks
after DC + AAV-Null/BMP4 treatment, as previously de-
scribed [19, 28]. The treatment status of the animal masked
from the investigator, sham controls and animals from DC+
AAV-Null and DC +AAV-BMP4 groups (n = 6 rats/group, 3
Table 2 List of primary and secondary antibodies used in this study
Antibody Source Dilution
Primary antibodies
Mouse anti-βIII-tubulin Sigma, Poole, UK 1:400
Rabbit anti-pSmad1 Cell Signalling Technology, Danvers, MA, USA 1:200
Rabbit anti-BMP4 Abcam, Cambridge, UK 1:400
Rabbit anti-Noggin Abcam, Cambridge, UK 1:400
Mouse anti-NF200 Sigma, Poole, UK 1:400
Mouse anti-GAP-43 Invitrogen, Paisley, UK 1:200
Rabbit anti-GFAP Sigma, Poole, UK 1:400
Secondary antibodies
Alexa-488 anti-rabbit Invitrogen, Paisley, UK 1:400
Alexa-488 anti-mouse Invitrogen, Paisley, UK 1:400
Alexa-594 anti-mouse Invitrogen, Paisley, UK 1:400
Alexa-594 anti-rabbit Invitrogen, Paisley, UK 1:400
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independent repeats; total n = 18 rats/group) were deeply
anaesthetised using 5% isofluorane, and deep anaesthesia
was maintained with 1.5% isofluorane for the duration of
the experiment, verified by the absence of a withdrawal
reflex to a peripheral pinch. Heart rate of approximately
360 beats/min was carefully monitored and body tempera-
ture was controlled using a feedback-controlled thermal
blanket set at 37 °C. Rats were fixed in a Kopf stereotaxic
apparatus (Kopf Instruments, Tujunga, CA, USA), a midline
incision was made through the skin, a laminectomy was
performed and the dura was cut to expose the thoracic and
lumbar spinal cord regions. Spinal cords were bathed in
warm mineral oil (37 °C). Silver wire electrodes (0.01″ di-
ameter; A-M Systems, Carlsborg, WA, USA) insulated ex-
cept at the tip were used to stimulate the DC axons at L1/2
and record CAP at T10-T9 at the surface of the midline
spinal cord. Pancuronium bromide (0.3 mg/kg, Sigma) was
injected intraperitoneally to minimise muscular contractions
throughout the experiment. The signal from the recording
electrode was amplified with filters set at 300–3000 Hz,
collected and Spike 2 software was used for data analysis
(Cambridge Electronic Design, Cambridge, UK).
Stimulating single current pulses (0.05 ms) were applied in
increasing increments (0.2, 0.3, 0.6, 0.8 and 1.1 mA), re-
corded at the detecting electrode and the amplified signals
were analysed using Spike 2 software (Cambridge
Electronic Design). CAP amplitudes and areas were then
calculated. At the end of each experiment, the dorsal half
of the spinal cord was transected between stimulating and
recording electrodes to confirm CAP abolition.
Functional Testing
Tape removal (sensory) and horizontal ladder crossing
(locomotor) functional tests after DC lesions and treatment
were carried out as described previously by us and others
[18, 19]. Functional deficits using the DC injury model
are mild, and hence, we used the horizontal ladder cross-
ing and tape removal tests as two of the five tests de-
scribed by Fagoe et al. [18] to reliably detect functional
deficits after injury. Fagoe et al. [18] and we [19] have
shown previously that functional deficits can be reliably
detected using these specific tests in the DC injury model.
Briefly, animals (n = 6 rats/group, 3 independent repeats;
total n = 18 rats/group) received training to master travers-
ing the rope and ladder for 2 weeks before functional
testing. All functional tests were performed 2–3 days be-
fore injury to establish baseline parameters. Animals were
then tested 2 days after DC lesion and then weekly for
6 weeks at the same time of day and each test performed
for three individual trials. For the horizontal ladder test,
the number of slips for each run was averaged by the total
number of steps to calculate the mean error rate. For the
tape removal test, the time it took for the animals to
detect and remove a piece of sticky tape attached to its
Table 3 Microarray analysis to show fold-differences in BMP4/Smad1 pathway genes compared to sham controls in rat DRGN 10 days after DC, SN
and pSN +DC lesions
Gene Description DC SN pSN +DC
smad 1 Mothers against decapentaplegic homologue 1 1.03 ± 0.05 3.01 ± 0.04*** 3.19 ± 0.04***
smad 2 Mothers against decapentaplegic homologue 2 1.03 ± 0.05 3.01 ± 0.04*** 3.19 ± 0.04***
smad 3 Mothers against decapentaplegic homologue 3 1.11 ± 0.10 1.04 ± 0.11 1.06 ± 0.04
smad 4 Mothers against decapentaplegic homologue 4 1.09 ± 0.03 2.01 ± 0.01** 2.00 ± 0.02**
smad 5 Mothers against decapentaplegic homologue 5 1.01 ± 0.03 3.58 ± 0.02*** 3.30 ± 0.03***
smad 6 Mothers against decapentaplegic homologue 6 1.01 ± 0.10 1.01 ± 0.05 1.02 ± 0.04
smad 7 Mothers against decapentaplegic homologue 7 1.09 ± 0.06 1.05 ± 0.08 1.03 ± 0.03
smad 8 Mothers against decapentaplegic homologue 8 0.99 ± 0.13 2.01 ± 0.02** 2.30 ± 0.03**
tgfβ1 Transforming growth factor β1 1.09 ± 0.10 1.41 ± 0.06 1.55 ± 0.01
tgfβ2 Transforming growth factor β2 1.09 ± 0.10 2.41 ± 0.16 2.35 ± 0.08
bmp-2 Bone morphogenetic protein 2 1.01 ± 0.02 1.41 ± 0.06 1.55 ± 0.03
bmp-4 Bone morphogenetic protein 4 1.09 ± 0.10 6.41 ± 0.16**** 6.66 ± 0.11***
bmp-7 Bone morphogenetic protein 7 1.00 ± 0.01 1.09 ± 0.10 1.06 ± 0.02
smurf1 Bone morphogenetic protein 7 1.00 ± 0.01 1.09 ± 0.10 1.06 ± 0.02
smurf2 Bone morphogenetic protein 7 1.04 ± 0.11 1.03 ± 0.09 1.01 ± 0.08
nogg Noggin 1.01 ± 0.08 −2.01 ± 0.09** − 2.05 ± 0.15**
Means ± SEM are shown from four different samples run in duplicate. **P < 0.001, ***P < 0.0001. Fold difference of > 2 were considered significant
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extended hind paw was recorded and used to calculate the
mean sensing time.
Statistical Analyses
Where indicated, significant differences on means ± SEM
were calculated between samples using SPSS Version 22
(IBM, NJ, USA) one-way analysis of variance (ANOVA)with
post hoc testing using Dunnet’s method.
For the ladder crossing functional test, data was analysed
using R package (www.r-project.org) as described previously
[18, 19]. Briefly, whole time-course testing of lesioned and
sham-treated animals were compared using binomial general-
ised linear mixed models (GLMM), fitted in R using package
lme4 with the glmer function and P values calculated using
parametric bootstrap. For the tape removal test, linear mixed
models (LMM) were calculated by model comparison using
the package pbkrtest, with the Kenward-Roger method [18,
19]. Individual time-points were also compared using inde-
pendent sample t test without correction.
Results
BMP4/Smad1 Pathway Activation in DRGN
Microarray data showed that the levels of mRNA for smad1,
smad2, smad4, smad5, smad8 and bmp4were all up-regulated
between 2.0- and 6.7-fold compared to sham controls, whilst
noggin was 2-fold down-regulated, in the DRG from both the
Fig. 2 Changes in Smad1/BMP4 signalling pathway. a Q-PCR con-
firmed good correlation between microarray and Q-PCR data. b
Immunohistochemistry for pSmad1 (green) in sections of regenerating
(SN, pSN +DC) and non-regenerating (IC, DC) NF200+ DRGN (red)
and of satellite cells (DAPI+ nuclei—blue). High levels of pSmad1 im-
munoreactivity were detected in occasional nuclei of regenerating SN and
many nuclei of pSN +DC DRGN. c Immunohistochemistry for BMP4
(green) in sections of regenerating (SN, pSN +DC) and non-regenerating
(IC, DC) NF200+ DRGN (red) and of satellite cells (DAPI+ nuclei–blue).
BMP4 immunoreactivity was detected in most regenerating SN and
pSN +DC DRGN. d Immunohistochemistry for Noggin in sections of
regenerating (SN, pSN +DC) and non-regenerating (IC, DC) DRGN.
Noggin immunoreactivity was highest in sham and DC whilst lower
levels of immunoreactivity were detected in regenerating SN and
pSN +DC DRGN. Scale bars in b–d = 50 μm
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SN and pSN +DC models (Table 3), but there was no change
in these mRNA levels in DRG from the DC model.
Confirmation of the heightened levels of BMP4/Smad1
mRNA in regenerating DRGN was provided by Q-PCR,
which reflected changes observed by microarray (Fig. 2a).
These results indicated that the BMP4/Smad1 signalling path-
way was highly active in DRG after SN and pSN +DC injury
when both SN and DC DRGN axonal projections were
regenerating.
Immunohistochemistry of Smad1, BMP4 and Noggin
In both sham controls and DC models, pSmad1 (Fig. 2b) and
BMP4+ immunoreactivity (Fig. 2c) were not detected in DRG
cells, but in SN and pSN +DCmodels, both were expressed in
DRGN soma and nuclei, the former in greater amounts than
the latter, but both proteins were absent from satellite cells. On
the other hand, Noggin+ immunoreactivity was present in
DRGN somata in sham controls and DC, but lower levels
were detected in regenerating SN and pSN + DC models
(Fig. 2d). These results confirmed the highly activated state
of BMP4/Smad1 signalling in DRGN of the regenerating SN
and pSN +DC models.
BMP4 Disinhibited DRGN Neurite Outgrowth In Vitro
and DC Axon Growth In Vivo, Independent of mTOR
There was no DRGN neurite outgrowth in control-untreated
DRG cultures prepared from intact rats in the presence of in-
hibitory concentrations of CME (Fig. 3a), whilst positive
control cultures treated with FGF2 showed significant
disinhibited neurite outgrowth (not shown). However, increas-
ing the concentration of BMP4 peptide, in the presence of
CME, disinhibited DRGN neurite outgrowth, increasing mean
DRGN neurite length (Fig. 3a, b) and the % DRGN with
neurites (Fig. 3c) to a maximum at a concentration 100 ng/ml,
beyond which disinhibited DRGN neurite outgrowth declined.
These results showed that activation of the BMP4/Smad1 sig-
nalling pathway promoted DRGN survival and disinhibited
neurite outgrowth in the presence of CME.
Intra-DRG injection of AAV-BMP4 significantly increased
BMP4 mRNA levels by 7.6 ± 0.3-fold (Fig. 3d) whilst BMP4
protein levels also increased significantly to 642 ± 83 ng/mg
of tissue, compared to 9.7 ± 1.2 ng/mg of tissue after DC +
AAV-Null treatment (Fig. 3e). These results demonstrated that
significant titres of BMP4mRNA and protein were induced in
DRGN after intra-DRG injection of AAV-BMP.
In DC +AAV-Null-treated rats (Fig. 4a–c), spinal cord cav-
itation (#) was observed at the lesion site (*) with GFAP+ im-
munoreactivity surrounding the lesion cavity (Fig. 4a), with
little or no GAP-43+ (red) regenerating axons observed (Fig.
4b, c). However, intra-DRG injection of AAV-BMP4 (Fig. 4d–
f) not only showed infiltration of GFAP+ astrocytes (green) into
the lesion site (Fig. 4d, d(i) = high power of boxed region in
Fig. 3d) but also promoted regeneration of ascending GAP43+
DC axons (red) into preserved tissue around areas of cavitation
(#) about the lesion site (Fig. 4e, f; e(i), f(i) = high power of
boxed regions in Fig. 4e, f, respectively). Quantification of the
total number of GAP43+ axons (red) traversing the lesion site
showed that 27 ± 4.4, 19.2 ± 2.2, 14.7 ± 2.4 and 11.33 ± 1.5%
Fig. 3 BMP4 disinhibits DRGN
neurite outgrowth in vitro. a
Escalating concentrations of
BMP4 up to 100 ng/ml increased;
b the length of the longest neurite;
and c % DRGN with neurites. d
Transduction with AAV-BMP4
significantly increased the levels
of BMP4 mRNA by ~ 8-fold >
DC+AAV-Null injection. e
ELISA confirmed that AAV-
BMP4 significantly increased the
titres of BMP4 in DRG
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of axons regenerated 0, 2, 4 and 6 mm beyond the lesion site,
respectively, in DC +AAV-BMP4-treated rats, whilst no axons
were present in DC+AAV-Null-treated groups (Fig. 3g). These
results suggested that AAV-BMP4 promoted DRGN axon re-
generation in long-tract ascending pathways of the rat spinal
cord, despite the presence of cavities.
AAV-BMP4 Promoted Electrophysiological Recovery
Across the DC Lesion Site
Superimposed CAP traces from representative animals from
the sham control, DC + AAV-Null and DC + AAV-BMP4
groups (Fig. 5a) showed that in the DC +AAV-Null groups,
the mean amplitude of the CAP wave was significantly atten-
uated compared to that of the sham control group (Fig. 5b).
The mean CAP amplitude was significantly reduced in the
DC +AAV-Null group, compared to sham controls (Fig. 5b).
However, significantly larger CAP amplitudes were observed
in DC +AAV-BMP4-treated rats at all stimulation intensities,
compared to those in the DC + AAV-Null treatment group
(P < 0.001; Fig. 5b). In sham controls, CAP area (0.65 ±
0.1 mV×ms) was reduced to 8.0 ± 7.8% of the CAP area in
DC +AAV-Null-treated groups (0.04 ± 0.05 mV ×ms) (Fig.
5c). CAP area in the DC +AAV-BMP4 group was significant-
ly larger (P < 0.001) than in the DC +AAV-Null group and
was increased to 61.5 ± 10% of that of the sham control group
(Fig. 5c). These results showed that in the AAV-BMP4 group,
axons conduct action potentials across the lesion site and that
conduction amplitudes had returned to > 60% of the original
intact spinal amplitudes, despite the presence of cavities.
AAV-BMP4 Promoted Functional Recovery
The mean sensing time for the tape removal test was between
12 and 25 s in sham-treated animals throughout the 6 weeks of
testing (Fig. 5d). We observed a significant increase of 77 ±
22 s at 2 days in DC +AAV-Null-treated groups in the time it
takes to sense and remove the adhesive tape decreasing to 39–
52 s from 4 weeks onwards. However, in DC +AAV-BMP4-
treated animals, the mean sensing time was significantly less
at 2 days after injury when compared to DC +AAV-Null-treat-
ed animals, taking only 39 ± 6 s to detect and remove the
adhesive tape (P < 0.001, independent sample t test). By
3 weeks after DC lesion, the mean sensing time in DC +
AAV-BMP4-treated animals was no different to that of
sham-treated control animals and significantly improved com-
pared to DC +AAV-Null-treated animals (P < 0.001, indepen-
dent sample t test). Over the whole-time course, there was a
significant reduction in the time taken to sense and remove the
adhesive tape in DC +AAV-BMP4-treated compared to DC +
AAV-Null-treated animals (linear mixed model, P < 0.001).
Over a 6-week testing period, there was a significant in-
crease in the error rates during horizontal ladder walking (gen-
eralised linear mixed model, P < 0.0011) (Fig. 5e) in DC +
AAV-Null-treated compared to DC +AAV-BMP4-treated an-
imals. The mean error ratio was significantly lower in DC +
Fig. 4 BMP4 promotes axon
regeneration in an in vivo rat
model that cavitates. a–c
Treatment with DC +AAV-Null
leads to cavity (#) formation at the
lesion site (*) with no evidence of
axon regeneration. d–f AAV-
BMP4 enhances DC axon regen-
eration despite the presence of
cavities (#), detected by GAP43+
staining (red) with GFAP+ astro-
cytes (green) also infiltrating the
lesion site (*). c, fMerged images
to show GFAP (green) and
GAP43 (red) double staining with
DAPI+ nuclei (blue). Inset d(i),
e(i) and f(i) = higher power views
of the boxed regions in d–f, re-
spectively. gQuantification of DC
axon regeneration at the lesion
site, rostral and caudal to the le-
sion. *** = P < 0.0001, ANOVA.
** = P < 0.001; * = P < 0.05,
ANOVA. Scale bars in a–f and
d(i)–f(i) = 100 μm
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AAV-BMP4 compared to DC +AAV-Null-treated animals at
2 days after injury (P < 0.001, independent sample t test) and
at 2–3 weeks (P < 0.001, independent sample t test) by which
time the error rate was no different to that of sham controls. A
significant functional deficit remained in DC + AAV-Null-
treated rats throughout the duration of the test. These results
demonstrated that AAV-BMP4 promoted significant sensory
and locomotor function recovery after DC injury in the rat,
despite the presence of cavities.
Discussion
In this study, we investigated the relative contribution of sig-
nalling through the BMP4/Smad1 pathway in promoting
long-tract DRGN axon regeneration after DC injury in the
rat model that cavitates and showed by microarray and immu-
nohistochemistry analyses that components of the BMP4/
Smad1 pathway were highly correlative with the regenerative
outcome seen after DC transection. For example, BMP4 and
Smad1 mRNA and protein were highly upregulated in both
regenerating paradigms whilst expression levels of the BMP4
suppressor Noggin were attenuated. Treatment of DRGN cul-
tures with BMP4 significantly disinhibited neurite outgrowth
in the presence of inhibitory concentrations of CME, whilst
AAV8-mediated delivery of BMP4 in the rat in vivo promoted
DC axon regeneration and electrophysiological, sensory and
locomotor improvements after DC injury, despite the presence
of cavities.
The PTEN/mTOR pathway has emerged as one key deter-
minant in regenerative success in the adult RGC [29–31] and
corticospinal tract [4, 32, 33]. However, pten deletion not only
promotes axon regeneration through mTOR-dependent mech-
anisms [30] but also throughmTOR-independent mechanisms
[34]. Numerous other studies have shown that mTOR activity
is not required for peripheral nerve regeneration [35–37].
Instead, peripheral sensory axon regeneration is thought to
be mediated by PI3K signalling via GSK3 inactivation and
subsequent gene expression, independent of mTOR-
mediated protein synthesis [37, 38].
Fig. 5 AAV-BMP4 promotes
preservation of spinal CAP across
the lesion site and functional
recovery. a Superimposed CAP
traces from representative animals
in sham, DC +AAV-Null and
DC+AAV-BMP4 treatment
groups. b Compared to sham
control, CAP amplitudes (mV)
were greatly attenuated in the
DC+AAV-Null group, but were
significantly improved in the
DC+AAV-BMP4 group
(P < 0.001, ANOVA). c Mean
CAP area at different stimulus
intensities record from sham was
significantly attenuated in the
DC+AAV-Null group, but sig-
nificantly improved in the DC +
AAV-BMP4 compared to the
DC+AAV-Null group
(**P < 0.001, ANOVA). d Mean
sensing time for the tape removal
test and mean error ratios for the e
horizontal ladder walking tests
show significant recovery of
function after AAV-BMP4 treat-
ment. #P < 0.05; ##P < 0.001,
generalised linear models.
**P < 0.001, independent sample
t test
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In DRGN, a possible PI3K/Akt axogenic signalling route,
independent of mTOR, is through the BMP4/Smad1 pathway
which influences a broad spectrum of intracellular signalling
pathways [12, 39, 40] including MAPK, GSK3-β, PI3K and
Akt. The DRGN axon growth promoted by NTF/Trk binding
and subsequent activation of the MAPK and PI3K/Akt effec-
tor pathways is arrested after suppression of BMP [13] prob-
ably because, in the absence of Smad1, transcription of the
NTF effectors Erk1/2 is blocked [10]. Within the BMP/Smad
pathway, raised BMP4 and Smad1, 2, 4, 5, 8 mRNA and
lowered Noggin mRNA levels correlated with complimentary
changes in BMP4, pSmad1 and Noggin protein in DRGN in
the DC, SN and pSN +DC models. Moreover, our observa-
tion that BMP4 disinhibited DRGN neurite growth on a CME
substrate in culture agrees with previous findings [15]. Both
SN axotomy and intra-DRG injection of BMP2/4 protein ac-
tivates Smad1 in DRGN and enhances DRGN neurite out-
growth, whilst DC transection fails to activate the Smad1
pathway [14].
Down-regulation of the BMP/Smad1 pathway occurs
during the age-related decline in axon growth potential
and, in adults, blockade of BMP signalling, by either phar-
macological inhibition or knockdown of Smad1, arrests the
initiation and elongation of DRGN neurites [13], whereas
activation of Smad1 by intrathecal injection of AAV-BMP4
stimulates DRGN axon regeneration through mouse DC
lesions [13]. However, BMP control of growth cone mo-
bility through regulation of actin dynamics is independent
of Smad1 and involves direct interaction between the tail
region of BMPRII and LIMK [41–44]. Levels of Noggin
mRNA were reduced in the SN and pSN + DC axon
regenerating paradigms but not in the non-regenerating
DC, agreeing with findings that Noggin inhibits BMP sig-
nalling by blocking type I/II BMPR binding sites [45] and
reducing DRGN neurite outgrowth. Conversely, suppres-
sion of Noggin potentiates SN axon regeneration in vivo
[15].
Despite contradictory reports that BMP4 inhibits axon
regeneration by promoting hypertrophic scarring [46] and
that Noggin promotes axon growth [15, 47] in the spinal
cord, we and others [13] have demonstrated DC axon
regeneration and functional recovery after delivery to
DRGN of either BMP4 peptide or AAV8-BMP4 after
intra-DRG and intrathecal injection in both mouse and
rat. Moreover, there was constitutive expression of
Noggin in DRGN in the DC, but a 2-fold reduction in
the SN and pSN + DC regenerating models, indicating
that future delivery to DRGN of a combination of
AAV8-BMP4 with a Noggin antagonist is expected to
significantly enhance DC axon regeneration further and
promote significant functional recovery, as shown by the
preservation of CAP and improvements in ladder walking
and tape removal tests. Our electrophysiological data
recorded cord dorsum potentials, which not only mea-
sured dorsal column activity but may have detected sig-
nals from diverse sources. For example, CDP is an evoked
spinal cord field potential that arises in the dorsal horn
interneurons of the spinal cord segments receiving inputs
from a stimulated peripheral nerve and can originate from
proximal sensory nerve, dorsal nerve root and spinal cord
dorsal horn function [48]. Therefore, it is likely that some
improvements may be due to preservation of these path-
ways in the AAV-BMP4-treated groups.
The beneficial effects of BMP4 delivery demonstrated in
our study are significant since previous work by Parikh et al.
(2011) using the same AAV8-BMP4 promoted DC axon re-
generation and functional recovery in the mouse, which does
not cavitate but instead fills the lesion site with fibrotic tissue
[16, 49]. SCI in the rat normally results in large cystic cavities
that extend rostrally and caudally to the original lesion site
[50]. Pathologically, rat SCI is more similar to that seen in
humans where spinal cord atrophy, myelomalacia, cyst and
syrinx formation occurs [51]. Therefore, our demonstration
of the benefits of BMP4 treatment after SCI in the rat is
translationally more relevant to the human condition.
Although we used AAV8 to deliver BMP4, which is not
considered translational since transgenes were injected 1 week
before DC injury, the study does demonstrate proof-of-
principle that activation of the BMP4/Smad1 pathway is im-
portant in promoting long-tract ascending DC axon regenera-
tion after injury. However, we have shown in the rat DC lesion
model that a non-viral delivery vector, in vivo-JetPEI, deliv-
ered plasmid DNAwith the same efficiency of transduction as
AAV and without activation of non-specific interferon re-
sponses, promoting similar DC axon regeneration, electro-
physiological and functional recovery [19]. We expect that
the same non-viral delivery vector can be used to safely de-
liver BMP4 and activate the BMP/Smad1 signalling pathway,
making the approach translationally relevant.
Thus, we have provided in vitro and in vivo evidence
that the BMP4/Smad1 pathway was activated in DRGN in
the regenerating SN and pSN + DC models but not in the
non-regenerating DC model. In vitro, BMP4 peptide
disinhibited significant DRGN neurite outgrowth and,
in vivo, AAV8-BMP4 promoted DC axon regeneration
and functional recovery without the need for an SN pre-
conditioning lesion, in a rat model of SCI that cavitates
like in humans. We conclude that BMP4 over-expression
promoted significant DRGN axon regeneration and en-
hanced recovery of lost function in the lesioned DC and
may be a potential therapy for SCI patients.
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